Published in Curr Treat Options Gastroenterol on February 01, 2006
Emerging issues in ulcerative colitis and ulcerative proctitis: individualizing treatment to maximize outcomes. Gastroenterol Hepatol (N Y) (2009) 0.81
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol (2010) 2.74
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc (2006) 2.73
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology (2007) 2.55
Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg (2008) 2.29
Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol (2006) 1.87
Comprehensive evaluation of inflammatory and noninflammatory sequelae of ileal pouch-anal anastomoses. Am J Gastroenterol (2005) 1.10
Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis (2012) 1.08
Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology (2010) 1.04
Differentiating risk factors for acute and chronic pouchitis. Clin Gastroenterol Hepatol (2005) 0.93
Hospital readmissions in patients with inflammatory bowel disease. Am J Gastroenterol (2013) 0.91
Measurement of nutrition status in Crohn's disease patients receiving infliximab therapy. Nutr Clin Pract (2008) 0.90
Retracted Molecular pathways underlying IBD-associated colorectal neoplasia: therapeutic implications. Am J Gastroenterol (2011) 0.88
Risk factors for clinical phenotypes of Crohn's disease of the ileal pouch. Am J Gastroenterol (2006) 0.87
Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis (2004) 0.81
Can we immunogenotypically and immunophenotypically profile patients who are at risk for pouchitis? Am J Gastroenterol (2004) 0.78
Random versus targeted biopsies for colorectal cancer surveillance in inflammatory bowel disease. Gastroenterol Hepatol (N Y) (2010) 0.77
Continuing Medical Education Questions: October 2015. Am J Gastroenterol (2015) 0.75
Quality commitment: the newly established American College of Gastroenterology Quality Council to meet the needs of clinical gastroenterology. Am J Gastroenterol (2013) 0.75
A case of refractory diarrhea. Cleve Clin J Med (2008) 0.75
Our Vision for the Future of Inflammatory Bowel Diseases: Research, Innovations, and Controversies. Inflamm Bowel Dis (2017) 0.75
Antiviral Treatment for Colonic Cytomegalovirus Infection in Ulcerative Colitis Patients Significantly Improved Their Surgery Free Survival. J Clin Gastroenterol (2016) 0.75
Chemoprevention of colorectal cancer: slow, steady progress. Cleve Clin J Med (2003) 0.75
Continuing Medical Education Questions: October 2015. Am J Gastroenterol (2015) 0.75